Steve Thorne
Company: KaliVir Immunotherapeutics
Job title: Chief Scientific Officer
Seminars:
Using Oncolytic Viruses to Target TGF-β in the Tumor Microenvironment 3:00 pm
Directly targeting tumors using OVs to avoid systematic toxicity for better patient response Targeting the TGF-β receptors with oncolytic viruses for strong immune response Uncovering preclinical success using OVs to show clinical efficacy New Data!Read more
day: Conference Day Two